**Sir,**

I read the article by [@bib2] with great interest, which appeared in your journal as *Br J Cancer*. The study aimed to evaluate the impact of the NQO1 gene polymorphism with cancer risk. Although the study provides preliminary evidence to consider NQO1 polymorphism as a risk factor for cancer; however, after careful reading of the article, a few important issues came out that must be addressed for further actions.

First, it appears that the authors somehow missed the statistical power in this study. Sample sizes remain a major issue in genetic case--control studies analysing the association of polymorphism with disease susceptibility. The authors did neither mention the statistical power of individual studies nor their overall meta-analysis. Hence, the study should obtain an adequate statistical power (80%) to estimate significant association accurately, which remains a primary criterion to perform such studies, especially from the venous blood of study subjects. Underpowered studies usually lead to false-positive associations and misinterpretations ([@bib1]). The authors also failed to mention the incidence rate of various cancers in the said study. The individual studies recruited in the present meta-analysis achieved the required statistical power is questionable and did not discuss in the text.

Second, the authors mention the sample size of Malik *et al* as 107 gastric cancer cases and 195 controls ([@bib3]). But the exact number of gastric cancer cases is 108 in the study by Malik *et al.* All these points suggest a thorough examination of the association observed in the said study, and must be clarified before concluding that NQO1 gene polymorphism is a potential marker of cancer.
